McKesson extends CVS Health pact through 2032: CVS Health stock yields 3.10 percent

Published on 10/05/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 106.10 billion, up 7.30 percent year over year. CVS Health stock costs EUR 77.34 on October 5, 2026 versus EUR 76.80.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) was trading at EUR 77.34 at Lang & Schwarz on October 5, 2026 at 1:12 p.m. CEST, up 0.70 percent from the EUR 76.80 prior close. On October 1, 2026, McKesson said it had agreed in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, while MarketBeat reported a quarterly dividend of USD 0.665 and a 3.10 percent annualized yield on October 4, 2026.

Distribution pact reaches 2032

The agreement covers deliveries to CVS Health mail-order and specialty pharmacies, retail pharmacies and distribution centers. The McKesson release says the arrangement remains subject to a definitive contract and identifies possible delays in signing as a risk.

For CVS Health, the extension reaches across several pharmacy channels rather than a single retail route. The commercial terms were not disclosed in the October 1, 2026 release, so the visible benefit is the longer distribution relationship rather than a quantified earnings contribution.

Revenue and guidance reset

Zacks said CVS Health generated USD 106.10 billion of revenue in the second quarter of 2026, up 7.30 percent year over year, while adjusted earnings per share reached USD 2.58, up 42.50 percent. Revenue also exceeded the consensus estimate of USD 100.03 billion, a USD 6.07 billion difference.

Management raised its full-year 2026 adjusted earnings guidance to USD 7.90-8.10 per share from USD 7.30-7.50, according to Zacks. The same update lifted the operating cash flow outlook to at least USD 11.5 billion from at least USD 9.5 billion, giving the guidance change a cash-generation component as well as an earnings component.

Stock remains below its yearly high

On the NYSE, CVS Health was last quoted at USD 86.46 on October 2, 2026 at 4:00 p.m. ET. Its one-year range was USD 69.51 to USD 110.68 on October 4, 2026, while finance data put market capitalization at USD 110.3 billion as of October 2, 2026.

At Lang & Schwarz, CVS Health stock was trading at EUR 77.34 on October 5, 2026 at 1:12 p.m. CEST, plus 0.70 percent versus the Lang & Schwarz prior close of EUR 76.80 on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.